HSGX - Histogenics Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7257
-0.1493 (-17.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.8750
Open0.7000
Bid0.7150 x 1200
Ask0.7400 x 800
Day's Range0.6708 - 0.7950
52 Week Range0.5000 - 3.3500
Volume12,478,444
Avg. Volume3,459,463
Market Cap45.012M
Beta (3Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-1.1390
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    Today’s Research Reports on Stocks to Watch: Immune Design and Histogenics

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Immune Design Corp. plummeted on the news that it is discontinuing a cancer vaccine program. Shares of Histogenics saw gains of over 12% as the company closed on a previously announced underwritten public offering. Immune Design Corp. shares closed down nearly 33.7% on Friday with about 3.3 million shares traded.

  • GlobeNewswire10 days ago

    Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants

    Histogenics Corporation (Histogenics) (HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. Canaccord Genuity LLC and BTIG, LLC acted as the joint book-running managers for the offering.

  • GlobeNewswire15 days ago

    Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants

    Histogenics Corporation (Histogenics) (HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. The gross proceeds to Histogenics from this offering are expected to be $17.0 million, before deducting underwriting discounts and commissions, and offering expenses payable by Histogenics.  The warrants are exercisable immediately upon issuance at a price of $0.70 per share of common stock and have a term of five years commencing on the date of issuance. All of the securities in the offering are being sold by Histogenics.  Histogenics intends to use the net proceeds from the offering to complete the biologics license application submission relating to NeoCart, prepare for commercialization of NeoCart following approval by the U.S. Food and Drug Administration, if at all, and for general corporate purposes.

  • GlobeNewswire16 days ago

    Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants

    Histogenics Corporation (Histogenics) (HSGX), a leader in the development of restorative cell therapies, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  All of the securities in the offering are to be sold by Histogenics. Canaccord Genuity LLC and BTIG, LLC are acting as the joint book-running managers for the offering.

  • GlobeNewswire24 days ago

    Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

    WALTHAM, Mass., Sept. 26, 2018-- Histogenics Corporation, a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today announced that the ...

  • Benzingalast month

    Histogenics Slips Below $1 Threshold After Knee Cartilage Candidate Fails Late-Stage Study

    Histogenics Corp (NASDAQ: HSGX) shares were losing more than half their market value Wednesday following the release of top-line data from the Phase 3 trial of Neocart, its pipeline candidate to treat knee cartilage damage. Histogenics, a developer of restorative cell therapies, said Neocart did not meet the primary endpoint of statistically significant improvement in pain and function in a dual threshold responder analysis a year after treatment relative to microfracture. In the modified Intent to Treat population, which excludes patients randomized but not treated with Neocart, 74.2 percent showed clinically meaningful improvement in pain and function compared to 62 percent of microfracture patients at one year, which was deemed to be statistically insignificant.

  • GlobeNewswirelast month

    Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage

    ‒Phase 3 Clinical Trial of NeoCart Did Not Meet Primary Endpoint of a Statistically Significant Improvement in Pain and Function in a Dual Threshold Responder Analysis One Year After Treatment as Compared ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of HSGX earnings conference call or presentation 9-Aug-18 12:30pm GMT

    Q2 2018 Histogenics Corp Earnings Call

  • Histogenics Sees Hammer Chart Pattern: Time to Buy?
    Zacks2 months ago

    Histogenics Sees Hammer Chart Pattern: Time to Buy?

    Histogenics has been struggling lately, but the selling pressure may be coming to an end soon.

  • Associated Press2 months ago

    Histogenics: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 13 cents per share. Losses, adjusted for non-recurring gains, were 25 cents per share. The results missed Wall Street expectations. The average ...

  • GlobeNewswire2 months ago

    Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results

    ‒Top-line Superiority Data from NeoCart ® Phase 3 Clinical Trial on Track for Third Quarter of 2018‒‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018‒‒ Expansion of Management ...

  • ACCESSWIRE2 months ago

    Histogenics Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Histogenics Corp. (NASDAQ: HSGX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. ...

  • GlobeNewswire3 months ago

    Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer

    Histogenics Corporation (Histogenics) (HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment of E. Lynne Kelley, M.D., FACS as its Chief Medical Officer. Dr. Kelley brings more than 20 years of executive management and surgical experience in medical affairs, clinical operations, regulatory affairs and product development to Histogenics. Dr. Kelley will join Histogenics’ executive team and assume responsibility for leading medical affairs strategy and building out the department in anticipation of NeoCart’s potential commercial launch.

  • GlobeNewswire3 months ago

    Histogenics Corporation to Report Second Quarter 2018 Financial Results on August 9, 2018

    A live audio webcast of the presentation will be available via the “Investor Relations” page of the Histogenics website, www.histogenics.com, or by clicking here.  A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the call.

  • GlobeNewswire3 months ago

    Histogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference

    WALTHAM, Mass., July 25, 2018-- Histogenics Corporation, a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley, ...

  • GlobeNewswire3 months ago

    Histogenics Chief Operating Officer, Stephen Kennedy Appointed to Advanced Regenerative Manufacturing Institute’s Technology Advisory Sub-Committee

    Histogenics Corporation (Histogenics) (HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Stephen Kennedy, Executive Vice President & Chief Operating Officer, has been appointed to the BioFabUSA Leadership Advisory Council and Technology Advisory Subcommittee (TASC) of the Advanced Regenerative Manufacturing Institute (ARMI). ARMI is a new public-private Manufacturing USA initiative that brings together a consortium of nearly 100 organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cell and gene-based therapies.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of HSGX earnings conference call or presentation 10-May-18 12:30pm GMT

    Q1 2018 Histogenics Corp Earnings Call

  • Associated Press5 months ago

    Histogenics: 1Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 52 cents per share. Losses, adjusted for non-recurring costs, were 20 cents per share. The company's shares closed at $2.60. A year ago, they ...

  • How Do Analysts See Histogenics Corporation (NASDAQ:HSGX) Performing Over The Next Few Years?
    Simply Wall St.6 months ago

    How Do Analysts See Histogenics Corporation (NASDAQ:HSGX) Performing Over The Next Few Years?

    In December 2017, Histogenics Corporation (NASDAQ:HSGX) released its latest earnings announcement, which signalled that losses became smaller relative to the prrior year’s level – great news for investors Below, I’veRead More...